Differentiating Cannabis and Hemp with the Cannabis Analyzer for Potency

CBD is growing in popularity as a medicinal treatment for inflammation, pain and anxiety. Since the passage of Agricultural Improvement Act of 2018, which legalized cannabis and hemp products under the FDA’s authority, the cannabis market has dramatically expanded. Prescriptions of marijuana derived compounds are commonplace in several states with more pharmaceutical treatments to follow. Hemp-derived CBD products and treatments abound. As of 2020, the only FDA approved drug for treating epilepsy is Epidiolex, which contains a purified form of CBD. The combination of THC and CBD has shown enhanced immune system in cancer patients, relaxed arteries in patients with heart disease and reduced muscle spasms in patients with Multiple Sclerosis. The U.S. Hemp Farming Act was signed into law in December, 2018. The law differentiates hemp from cannabis based on its total psychoactive content or Total THC (% THCA + % d9-THC). Hemp is considered < 0.3 wt. %. The purpose for this study is to build a simple and rugged HPLC method for differentiating cannabis and hemp.

Content Type:
Poster
Document Number:
P050
Product Type:
High Performance Liquid Chromatography (HPLC & UHPLC)
Keywords:
Cannabis, Hemp, Cannabis & Hemp Testing Solutions, Cannabis Analyzer for Potency
Language:
English
File Name:
Pittcon2021-P050-Differentiating-Cannabis-and-Hemp-with-the-Cannabis-Analyzer-for-Potency.pdf
File Size:
621kb

View Article Question about this literature?

For Research Use Only. Not for use in diagnostic procedures.

Top of This Page